Medicare AdvantagePrior AuthHigh impact
Orencia (abatacept) Intravenous (Revised)
Humana·Rheumatology, Hematology, Oncology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jul 22, 2026
Summary
This is a revised Medicare Advantage prior authorization policy for Orencia (abatacept) intravenous effective January 1, 2026, updated July 22, 2026. The policy establishes specific step-therapy requirements for four indications (Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, and Graft vs. Host Disease prophylaxis), requiring documented prior therapy or contraindication with specified biologics before approval. Key restriction: Orencia cannot be used in combination with other biologics, and Medicare Part B continuation therapy within 365 days is exempt from step-therapy requirements.
Action Required
By January 1, 2026 (or immediately if already past): (1) Billing and Prior Authorization teams must update authorization system to enforce step-therapy requirements for Orencia IV across all four indications. (2) For Rheumatoid Arthritis and Psoriatic Arthritis: Require evidence of prior therapy, contraindication, or intolerance with Remicade/Inflectra/Infliximab OR Simponi Aria before approval; for PSA also require prior experience with preferred ustekinumab products. (3) For Juvenile Idiopathic Arthritis: Require prior therapy with TWO of the following—preferred adalimumab products, Enbrel, or Rinvoq. (4) For all indications: BLOCK approvals if member is on concurrent biologic therapy (Cosentyx, Enbrel, adalimumab, Kevzara, Remicade, etc.). (5) For Medicare Part B requests: Bypass step-therapy if continuation of therapy within past 365 days—flag these claims as exempt. (6) Update prior authorization request forms and provider portals to capture documented prior therapy details and rule out concurrent biologics. (7) Educate providers on the combination therapy exclusion to prevent claim denials. Failure to implement will result in inappropriate approvals and potential claim denials during adjudication.